Please note that Embrace2 is no longer available for purchase. We have recently launched our newest epilepsy monitoring solution, EpiMonitor, in the following countries: United States, United Kingdom, Germany, France, Denmark, Sweden, Belgium, Luxembourg, Austria, Liechtenstein, Ireland, Spain, Italy, Netherlands, Malta, and Finland. Please visit this page to learn more about it: What’s new on EpiMonitor. Embrace2 services (Alert App, Mate App) will remain active for current users. The Empatica Support Team will continue to provide support for all Embrace2 users.
We are constantly validating and improving our algorithm, and to test its accuracy we collaborate with top hospitals.
In December 2018, clinical testing was performed to demonstrate the ability of the Embrace as a seizure monitoring aid.
During the clinical testing, 141 patients diagnosed with epilepsy were continuously monitored. This lead to 9806 hours or 409 days of data, including 54 generalized tonic-clonic seizures. The trial was supervised by 3 board-certified clinical neurologists who independently examined the data. Embrace's algorithm was shown to detect 98% of the seizures, and the false alarm rate was 0.94 per day.
The full details of this work are included in this document, in the section titled Clinical Testing.
We can’t guarantee that Embrace will detect every single seizure. It is not meant to substitute your current seizure monitoring practices, but rather to serve as a supplement in expediting first-response time.